The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.
More from Ben Fidler
Lilly’s oral SERD gets FDA nod in advanced breast cancer
No Comments
Leave a comment Cancel